Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Apr;40(2):e70010.
doi: 10.1002/jca.70010.

The Impact of Efgartigimod on Utilization of Therapeutic Plasma Exchange Procedures for Myasthenia Gravis in One Tertiary Medical Center

Ashley J Crosby  1 , Mariama Evans  1 , Danielle L V Maracaja  1 , Yara A Park  1 , James F Howard Jr  2 , Matthew S Karafin  1
Affiliations

The Impact of Efgartigimod on Utilization of Therapeutic Plasma Exchange Procedures for Myasthenia Gravis in One Tertiary Medical Center

Ashley J Crosby et al. J Clin Apher. 2025 Apr.

Abstract

Myasthenia gravis (MG) is an autoimmune disorder caused by autoantibodies against proteins of the neuromuscular junction, such as the acetylcholine receptor (AChR). While therapeutic plasma exchange (TPE) has been a standard chronic therapy for patients with poorly controlled MG, new medications have recently been approved by the FDA for such patients. We report the impact of a new therapy, efgartigimod, on the number of therapeutic plasma exchanges performed on patients with generalized MG in our apheresis unit. A retrospective chart review was performed for patients with MG between 2018-2019 (pre-efgartigimod) and 2022-2023 (post-efgartigimod). We evaluated any changes between the two periods, including the total number of MG patients, the proportion of TPEs that were performed for MG, and the proportion of inpatient TPEs for MG. A statistically significant reduction (p < 0.0001) was observed in the proportion of total TPE procedures for MG between the two time periods. In AChR-antibody positive (AChR-Ab +) patients who received both inpatient and outpatient procedures, there was a significant increase in the proportion of inpatient procedures post-efgartigimod (p = 0.0035). Our study demonstrated a decrease in the overall use of chronic TPE for MG over the 2-year period following the release of efgartigimod. However, there will remain a role for TPE in the setting of acute MG flares, the inpatient setting, during pregnancy, and in those who do not tolerate the new medications.

Keywords: efgartigimod; myasthenia gravis; neonatal fc receptor; therapeutic plasma exchange.

PubMed Disclaimer

References

    1. L. Connelly‐Smith, C. R. Alquist, N. A. Aqui, et al., “Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence‐Based Approach From the Writing Committee of the American Society for Apheresis: The Ninth Special Issue,” Journal of Clinical Apheresis 38, no. 2 (2023): 77–278, https://doi.org/10.1002/jca.22043.
    1. N. E. Gilhus, “Myasthenia Gravis,” New England Journal of Medicine 375, no. 26 (2016): 2570–2581, https://doi.org/10.1056/NEJMra1602678.
    1. Y. A. Heo, “Efgartigimod: First Approval,” Drugs 82, no. 3 (2022): 341–348, https://doi.org/10.1007/s40265‐022‐01678‐3;
    1. Erratum in: Drugs. 2022 Apr;82(5):611, https://doi.org/10.1007/s40265‐022‐01712‐4.
    1. J. D. Lünemann, “Getting Specific: Targeting Fc Receptors in Myasthenia Gravis,” Nature Reviews. Neurology 17, no. 10 (2021): 597–598, https://doi.org/10.1038/s41582‐021‐00547‐z.

LinkOut - more resources